Guardant Health Stock Forecast, Price & News

+2.81 (+2.32 %)
(As of 06/14/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume21,767 shs
Average Volume1.02 million shs
Market Capitalization$12.51 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

Guardant Health logo

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

103rd out of 2,099 stocks

Medical Laboratories Industry

4th out of 40 stocks

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Guardant Health (NASDAQ:GH) Frequently Asked Questions

Is Guardant Health a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health
or view top-rated stocks.

What stocks does MarketBeat like better than Guardant Health?

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Guardant Health

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.82) by $0.33. The company had revenue of $78.67 million for the quarter, compared to the consensus estimate of $74.28 million. Guardant Health had a negative trailing twelve-month return on equity of 30.60% and a negative net margin of 112.70%. The firm's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share.
View Guardant Health's earnings history

How has Guardant Health's stock been impacted by COVID-19?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GH stock has increased by 96.6% and is now trading at $123.74.
View which stocks have been most impacted by COVID-19

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $360 million-$370 million, compared to the consensus revenue estimate of $367.76 million.

What price target have analysts set for GH?

11 brokers have issued 12 month price objectives for Guardant Health's stock. Their forecasts range from $135.00 to $195.00. On average, they expect Guardant Health's share price to reach $167.50 in the next year. This suggests a possible upside of 35.4% from the stock's current price.
View analysts' price targets for Guardant Health
or view top-rated stocks among Wall Street analysts.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Mr. AmirAli Talasaz, Pres, COO & Chairman (Age 41, Pay $914.91k)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 42, Pay $914.91k)
  • Dr. Richard B. Lanman, Advisor (Age 66, Pay $540.15k)
  • Mr. Michael Bell, Chief Financial Officer (Age 52)
  • Mr. Kumud Kalia, Chief Information Officer
  • Mr. John G. Saia, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
  • Ms. Amelia Merrill, VP of People
  • Mr. Mark Jacobstein, Chief User Engagement Officer
  • Mr. Andy Ament, Sr. VP of Operations
  • Mr. Daniel Simon, Sr. VP of Biopharma Bus. Devel.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional investors include SB Investment Advisers UK Ltd. (6.11%), BlackRock Inc. (5.34%), Morgan Stanley (4.38%), Clearbridge Investments LLC (3.02%), Viking Global Investors LP (2.89%) and Jennison Associates LLC (2.70%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health

Which institutional investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Viking Global Investors LP, Morgan Stanley, Jennison Associates LLC, Lord Abbett & CO. LLC, JPMorgan Chase & Co., SB Investment Advisers UK Ltd., and Clearbridge Investments LLC. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health
or view top insider-selling stocks.

Which institutional investors are buying Guardant Health stock?

GH stock was acquired by a variety of institutional investors in the last quarter, including Coatue Management LLC, Polar Capital Holdings Plc, Fred Alger Management LLC, Orbimed Advisors LLC, Capital International Investors, Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., and Franklin Resources Inc..
View insider buying and selling activity for Guardant Health
or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $123.74.

How much money does Guardant Health make?

Guardant Health has a market capitalization of $12.51 billion and generates $286.73 million in revenue each year. The company earns $-253,780,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 864 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is

Where are Guardant Health's headquarters?

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.